Arcadia Biosciences Q2 2024 GAAP EPS $0.78 Misses $1.55 Estimate, Sales $1.306M Beat $925.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcadia Biosciences (NASDAQ:RKDA) reported Q2 2024 earnings per share (EPS) of $0.78, missing the analyst consensus estimate of $1.55 by 49.68%. However, the company reported quarterly sales of $1.306 million, beating the analyst consensus estimate of $925,000 by 41.19%. This represents a 0.69% increase over sales of $1.297 million in the same period last year.
August 13, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcadia Biosciences reported Q2 2024 EPS of $0.78, missing estimates by 49.68%, but sales of $1.306 million beat expectations by 41.19%. Sales increased by 0.69% YoY.
The significant miss on EPS is a negative indicator, but the strong sales performance and year-over-year growth provide a counterbalance. The mixed results suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100